371 related articles for article (PubMed ID: 26527155)
1. miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease.
Mushtaq G; Greig NH; Anwar F; Zamzami MA; Choudhry H; Shaik MM; Tamargo IA; Kamal MA
Med Chem; 2016; 12(3):217-25. PubMed ID: 26527155
[TBL] [Abstract][Full Text] [Related]
2. An overview of circulating cell-free microRNAs as putative biomarkers in Alzheimer's and Parkinson's Diseases.
Batistela MS; Josviak ND; Sulzbach CD; de Souza RL
Int J Neurosci; 2017 Jun; 127(6):547-558. PubMed ID: 27381850
[TBL] [Abstract][Full Text] [Related]
3. Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathology.
Burgos K; Malenica I; Metpally R; Courtright A; Rakela B; Beach T; Shill H; Adler C; Sabbagh M; Villa S; Tembe W; Craig D; Van Keuren-Jensen K
PLoS One; 2014; 9(5):e94839. PubMed ID: 24797360
[TBL] [Abstract][Full Text] [Related]
4. Specific Signatures of Serum miRNAs as Potential Biomarkers to Discriminate Clinically Similar Neurodegenerative and Vascular-Related Diseases.
Barbagallo C; Mostile G; Baglieri G; Giunta F; Luca A; Raciti L; Zappia M; Purrello M; Ragusa M; Nicoletti A
Cell Mol Neurobiol; 2020 May; 40(4):531-546. PubMed ID: 31691877
[TBL] [Abstract][Full Text] [Related]
5. Morphometric and Nanomechanical Screening of Peripheral Blood Cells with Atomic Force Microscopy for Label-Free Assessment of Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis.
Taneva SG; Todinova S; Andreeva T
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762599
[TBL] [Abstract][Full Text] [Related]
6. miRNAs as biomarkers of neurodegenerative disorders.
Viswambharan V; Thanseem I; Vasu MM; Poovathinal SA; Anitha A
Biomark Med; 2017 Feb; 11(2):151-167. PubMed ID: 28125293
[TBL] [Abstract][Full Text] [Related]
7. Several miRNAs derived from serum extracellular vesicles are potential biomarkers for early diagnosis and progression of Parkinson's disease.
He S; Huang L; Shao C; Nie T; Xia L; Cui B; Lu F; Zhu L; Chen B; Yang Q
Transl Neurodegener; 2021 Jul; 10(1):25. PubMed ID: 34315539
[TBL] [Abstract][Full Text] [Related]
8. Ultrasensitive detection of blood biomarkers of Alzheimer's and Parkinson's diseases: a systematic review.
Singh K; Cheung BM; Xu A
Biomark Med; 2021 Dec; 15(17):1693-1708. PubMed ID: 34743546
[No Abstract] [Full Text] [Related]
9. Are circulating microRNAs peripheral biomarkers for Alzheimer's disease?
Kumar S; Reddy PH
Biochim Biophys Acta; 2016 Sep; 1862(9):1617-27. PubMed ID: 27264337
[TBL] [Abstract][Full Text] [Related]
10. Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease.
Geekiyanage H; Jicha GA; Nelson PT; Chan C
Exp Neurol; 2012 Jun; 235(2):491-6. PubMed ID: 22155483
[TBL] [Abstract][Full Text] [Related]
11. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
Williams SM; Schulz P; Sierks MR
Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
[TBL] [Abstract][Full Text] [Related]
12. Recent developments in circulating biomarkers in Parkinson's disease: the potential use of miRNAs in a clinical setting.
Teixeira Dos Santos MC; Bell R; da Costa AN
Bioanalysis; 2016 Dec; 8(23):2497-2518. PubMed ID: 27855513
[TBL] [Abstract][Full Text] [Related]
13. Tiny But Mighty: Promising Roles of MicroRNAs in the Diagnosis and Treatment of Parkinson's Disease.
Wang Y; Yang Z; Le W
Neurosci Bull; 2017 Oct; 33(5):543-551. PubMed ID: 28762215
[TBL] [Abstract][Full Text] [Related]
14. Circulating miRNAs as biomarkers for neurodegenerative disorders.
Grasso M; Piscopo P; Confaloni A; Denti MA
Molecules; 2014 May; 19(5):6891-910. PubMed ID: 24858274
[TBL] [Abstract][Full Text] [Related]
15. The Immune System and Neuroinflammation as Potential Sources of Blood-Based Biomarkers for Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.
Clark LF; Kodadek T
ACS Chem Neurosci; 2016 May; 7(5):520-7. PubMed ID: 27046268
[TBL] [Abstract][Full Text] [Related]
16. Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease.
Pulliam L; Sun B; Mustapic M; Chawla S; Kapogiannis D
J Neurovirol; 2019 Oct; 25(5):702-709. PubMed ID: 30610738
[TBL] [Abstract][Full Text] [Related]
17. A panel of four decreased serum microRNAs as a novel biomarker for early Parkinson's disease.
Dong H; Wang C; Lu S; Yu C; Huang L; Feng W; Xu H; Chen X; Zen K; Yan Q; Liu W; Zhang C; Zhang CY
Biomarkers; 2016; 21(2):129-37. PubMed ID: 26631297
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein E4 serum concentration for increased sensitivity and specificity of diagnosis of drug treated Alzheimer's disease patients vs. drug treated parkinson's disease patients vs. age-matched normal controls.
Goldknopf IL; Park HR; Sabbagh M
Curr Alzheimer Res; 2012 Dec; 9(10):1149-67. PubMed ID: 22950864
[TBL] [Abstract][Full Text] [Related]
19. Circulatory miR-223-3p Discriminates Between Parkinson's and Alzheimer's Patients.
Mancuso R; Agostini S; Hernis A; Zanzottera M; Bianchi A; Clerici M
Sci Rep; 2019 Jun; 9(1):9393. PubMed ID: 31253822
[TBL] [Abstract][Full Text] [Related]
20. Combinatory microRNA serum signatures as classifiers of Parkinson's disease.
Patil KS; Basak I; Dalen I; Hoedt E; Lange J; Lunde KA; Liu Y; Tysnes OB; Forsgren L; Aarsland D; Neubert TA; Larsen JP; Alves G; Møller SG
Parkinsonism Relat Disord; 2019 Jul; 64():202-210. PubMed ID: 31003905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
